Beam Therapeutics.
American healthcare company
- Reports this week
- 1
- Active events
- 1
- Connections
- 42
What's happening
Active this week
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Redmile Group LLC trimmed its position in Beam Therapeutics.Some support1 report
-
Cathie Wood has acquired and continues to acquire shares of Beam Therapeutics.Some support2 reports
-
Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.Some support4 reports
-
Beam Therapeutics and Prime Medicine are competing for market share in the AATD gene-editing space, with an arbitration ruling favoring Prime's program.Some support1 report
-
Sana Biotechnology, based in Seattle, presented promising cell therapy data on July 3, 2025, involving a gene editing system and potential benefits from Trump-era tariffs.Speculative1 report
-
Ashish Gupta, an associate professor at the University of Minnesota, was an investigator in the BEACON trial as of July 3, 2025.Speculative1 report
-
H.C. Wainwright reiterated a Buy rating for Beam Therapeutics on July 6, 2025.Speculative1 report
-
Market expects earnings based on consensus outlook for Beam Therapeutics, announced on July 29, 2025.Some support1 report
-
John Evans was appointed chief executive officer of Beam Therapeutics on August 5, 2025.Some support1 report
-
FDA granted RMAT designation to Beam Therapeutics' drug candidate BEAM-101.Some support2 reports
-
Beam Therapeutics participated in investor conferences held in Boston on August 25, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Beam Therapeutics
Events traced to Beam Therapeutics, step by step, newest firstAround Beam Therapeutics this week
News at the entities that move Beam Therapeutics most-
Cathie Wood StructuralThe Hong Kong Web3 Festival 2027 is being held in Hong Kong to examine developments in the digital asset industry.Moves Beam Therapeutics
-
FDA StructuralFDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.Moves Beam Therapeutics
-
Ark Invest TransactionalArk Invest made multiple trades on November 6, 2026, buying shares of SpaceX and Nvidia while selling Broadcom.Moves Beam Therapeutics
-
SEC StructuralGap Inc. filed with the SEC regarding institutional investment activity, and Jefferies downgraded its stock rating and target price.Moves Beam Therapeutics
-
William P. Blair TransactionalWilliam Blair raised SEI Investments rating to outperform, while Keefe, Bruyette & Woods also raised its price objective on the stock.Moves Beam Therapeutics
-
Bank of America Mentioned togetherBank of America and Citigroup adjusted target prices and raised price objectives for BDX stock.Moves Beam Therapeutics
Connections
The 16 strongest of 42, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Cathie Wood Structural
Cathie Wood holds and continues to acquire shares in Beam Therapeutics.
-
FDA Structural
The FDA formally regulates Beam Therapeutics and grants critical designations and clearances for its drug candidates.
-
William P. Blair Transactional
Analyst William Blair upgraded shares of Beam Therapeutics to strong-buy.
-
Ark Invest Transactional
Ark Invest is actively purchasing or increasing its investment stake in Beam Therapeutics.
-
CRISPR Therapeutics Operational
Both companies are actively competing in the gene-editing space, developing therapies for blood disorders.
-
SEC Structural
Beam Therapeutics is subject to ongoing regulatory oversight and disclosure requirements mandated by the SEC.
-
MarketBeat Mentioned together
MarketBeat aggregates and reports financial data, including consensus ratings and price targets, for Beam Therapeutics.
-
Novavax Operational
Both companies are healthcare firms actively competing for investment capital.
Show all 16 connections
-
Ark Mentioned together
Ark funds are observed tracking Beam Therapeutics stock as part of their investment strategy.
-
Bank of America Mentioned together
Bank of America provides financial ratings and price targets for Beam Therapeutics.
-
Amy Simon Structural
Amy Simon is identified as an insider of Beam Therapeutics, evidenced by the sale of company stock.
-
Citigroup Mentioned together
Citigroup provided financial analysis, lifting its price objective for Beam Therapeutics.
-
Wedbush Securities Mentioned together
Wedbush Securities provides investment ratings and coverage for Beam Therapeutics.
-
Cambridge Shared context
Beam Therapeutics is headquartered in Cambridge, Massachusetts.
-
Nasdaq Shared context
Beam Therapeutics is listed on the Nasdaq exchange.
-
BioTech Mentioned together
The single snapshot only describes Beam Therapeutics as a healthcare company and provides no evidence of a relationship with BioTech.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
2 eventsJuly 2026
4 events- Redmile Group LLC trimmed its position in Beam Therapeutics.
- Cathie Wood has acquired and continues to acquire shares of Beam Therapeutics.
- Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.
- Beam Therapeutics and Prime Medicine are competing for market share in the AATD gene-editing space, with an arbitration ruling favoring Prime's program.
Show 1 earlier month
June 2026
7 events- Sana Biotechnology, based in Seattle, presented promising cell therapy data on July 3, 2025, involving a gene editing system and potential benefits from Trump-era tariffs.
- Ashish Gupta, an associate professor at the University of Minnesota, was an investigator in the BEACON trial as of July 3, 2025.
- H.C. Wainwright reiterated a Buy rating for Beam Therapeutics on July 6, 2025.
- Market expects earnings based on consensus outlook for Beam Therapeutics, announced on July 29, 2025.
- John Evans was appointed chief executive officer of Beam Therapeutics on August 5, 2025.
- FDA granted RMAT designation to Beam Therapeutics' drug candidate BEAM-101.
- Beam Therapeutics participated in investor conferences held in Boston on August 25, 2025.